The recent reintroduction of the Pasteur Bill seeks to address the global threat that antimicrobial-resistant (AMR) infections pose, one subscription contract at a time.
Antimicrobial resistance (AMR) happens when microbes such as bacteria, viruses and fungi change over time and stop responding to medicine. Their failure to respond makes it harder to treat infections, potentially resulting in spread, serious illness or death.
In today’s AMR drug discovery sector, pharmaceutical companies find it challenging to profit from new innovative drugs because, rightfully, hospitals reserve these drugs for only advanced cases. As a result, the current approach reduces the financial incentive to make these drugs, contributing to global concern about AMR infections and their impact…
Read the article in Pharmaceutical Technology.